Previous
Pause
Next
Skip to Navigation
↓
Projects
Year
Year
Year
-Year
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Researcher
- Any -
Afif
dyllanes
usuario_prueba
Almeida e Silva, Filomena Augusta
Angás Pajas, Jorge
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
Espina Cadena, Laura
Fernandez Antoran, David
Gil Hernández, Vanesa
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Gómez Candón, David
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Köhler , Ralf
Lopes de Sousa Martins, Pedro Alexandre
Martín Yebra, Alba
Martínez Delgado, David
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Philippidis , George
Ramón García, Santiago
Roque , Carla
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
Sánchez Martínez, Diego
Velasco Lozano, Susana
Íñiguez Dieste, David
Fecha
Fecha
Year
-Year
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Status
- Any -
Achieved
In processing
Reject
Title
Year
Understanding the contribution of Kaftrio to antimicrobial therapies against non-tuberculous mycobacteria in cystic fibrosis
2024 - 2026
Shortening Buruli Ulcer treatment: WHO recommended vs. a novel beta-lactam-containing therapy - Phase III evaluation in West Africa
2021 - 2025
New Weapons Against Mycobacterium abscessus and other Non-Tuberculous Mycobacteria (Project extension)
2021 - 2022
New Weapons Against Mycobacterium abscessus and other Non-Tuberculous Mycobacteria
2020 - 2021
Desarrollo de un modelo 3D de infección por SARS-CoV-2 de organoides primarios pulmonares humanos como plataforma de ensayo para nuevas terapias anti-COVID19
2020 - 2021
Screening of the FDA approved drug library with a primary human 3D Lung Organoid Model of SARS- CoV-2 infection
2020 - 2021
Beta-lactam containing regimen for the shortening of Buruli ulcer disease therapy: comparison of 8 weeks standard therapy (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate therapy [RC8 vs. RCA4].
2020 - 2023
BCG revaccination for healthcare workers in SARS-CoV-2 pandemic
2020 - 2022
Designing optimal regimes for tuberculosis therapy using one-step high content dynamic in vitro kill kinetic assay linked to hollow fibre studies.
2020 - 2022
EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS
2020 - 2023
DESARROLLO DE NUEVAS TERAPIAS ANTIMICROBIANAS MEDIANTE EL REPOSICIONAMIENTO DE FÁRMACOS EN COMBINACIONES SINÉRGICAS Y MODELOS DINÁMICOS FARMACOLÓGICOS: IMPLEMENTANDO UNA NUEVA TECNOLOGÍA INNOVADORA EN ARAGÓN
2019 - 2020
Discovery and development of tigecycline enhancer in Klebsiella pneumoniae
2018 - 2018
Identification of novel therapies for difficult to treat cystic fibrosis pulmonary infections caused by mycobacteria using an innovative technology: synergy screens of clinically approved drugs
2018 - 2019
Predicting optimal partners, combinatorial dosing schedules and clinical outcomes of beta-lactams using PKPD and mechanistic in vitro models
2018 - 2020
Beta-lactams for Tuberculosis Treatment
2018 - 2020
Desarrollo de modelos farmacológicos para la predicción de terapias óptimas que incluyan beta-lactámicos en el tratamiento de la tuberculosis
2018 - 2018
Estrategias innovadoras de reposicionamiento de fármacos para la identificación de nuevas terapias contra las infecciones causadas por micobacterias no tuberculosas en pacientes de Fibrosis Quística.
2018 - 2018
X Congreso Nacional de Micobacterias - MycoZAR
2017 - 2018